Breaking News
Get 45% Off 0
💰 With a 129% YTD gain in the bag, these are our AI’s top global picks for March
Read now

Big Pharma Stocks: Who’s Leading the Race and Who’s Slipping?

By The Tokenist (Timothy Fries )Stock MarketsAug 20, 2024 15:44
ca.investing.com/analysis/big-pharma-stocks-whos-leading-the-race-and-whos-slipping-200606795
Big Pharma Stocks: Who’s Leading the Race and Who’s Slipping?
By The Tokenist (Timothy Fries )   |  Aug 20, 2024 15:44
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
MRK
+0.87%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
VKTX
+2.65%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Over the last decade, the pharma sector has undergone significant restructuring. On the upside, big data, machine learning, and predictive analytics have streamlined drug pipelines, enabling greater technology fragmentation into new drug product cycles.

According to McKinsey & Company, the mRNA vaccine tech alone expanded from 11% to 21% of the development pipeline beyond C19. At the same time, GLP-1 drugs reshaped obesity treatment along with gene therapies for rare diseases. Moving forward, AI-powered automation is expected to cut process timelines by 60% – 70%, per PwC analysis.

On the downside, the pharma landscape has become more competitive with higher PI-PIII trial spending, especially across blood, cancer, and infections sectors. Inflation and supply chain problems further impacted profit margins, exacerbated by the STEM labor shortage. According to a CBRE report 2022, workers from life sciences research greatly outpaced all other US occupations in the last two decades, at 79% vs 8%, respectively.

Lastly, the Inflation Reduction Act provision allowing Medicare to negotiate drug prices placed pressure on how biotech companies value drug returns. With all these trials, relative newcomer Viking Therapeutics (NASDAQ:VKTX) has been the most performant biopharma stock in 2024 at 244% YTD gains. In contrast, pharma giant Merck & Company Inc (NYSE:MRK) has flatlined at 1.2% YTD returns.

But which one is more prospective for the long haul?

Viking Therapeutics

Specializing in metabolic and endocrine disorders, this San Diego clinical-stage firm aims to tackle Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY). Of all medical conditions, it is difficult to find one that is more debilitating than obesity, triggering not only other conditions but greatly exacerbating absenteeism and presenteeism in workplace environments.

Viking Therapeutics Inc's leading candidate to tackle this massive problem, which affects one in three US adults, is VK2735. After completing the Phase 2 VENTURE trial, which was double-blind, placebo-controlled, and randomized, the dual GLP-1/GIP agonist showed a 14% body weight reduction after 13 weeks.

With a favorable safety profile, an oral version of VK2735 is currently in Phase 1 trial. Outside of obesity, Viking has VK2809 for fatty liver disease NASH (nonalcoholic steatohepatitis) in Phase 2b and VK0214 for rare genetic disorder X-linked adrenoleukodystrophy (X-ALD) in Phase 1b.

Of the four drugs, VK2735 is the company’s main valuation driver. This is not surprising given the total addressable market (TAM) for anti-obesity medications (AOMs) of up to $100 billion by 2030 (~16x), according to Goldman Sachs (NYSE:GS). Conversely, VKTX stock presents investors with a high reward, high risk exposure.

But, given the fact that VK2735 exploits the same hormonal mechanism as found in Novo Nordisk and Eli Lilly AOMs, it could be argued that the risk is minimal. This will be determined in the Phase 3 results.

Presently priced at $66.25, VKTX stock is still closer to its 52-week average of $40.09 than to its 52-week high of $99.41 per share. Based on 9 analyst inputs aggregated by Nasdaq, the average VKTX price target is $113.22 per share. With $90 as the low estimate, this makes VKTX a compelling case for exposure entry.

Merck & Company, Inc.

Although stock performance was lacking, this global pharmaceutical company had a productive year. Merck & Company Inc (NYSE:MRK) acquired Abceutics, a pre-clinical stage startup that improves the safety and efficacy of antibody-drug conjugates, for $208 million.

A month prior, in March, Merck acquired Harpoon Therapeutics (NASDAQ:HARP) to enhance its oncology pipeline worth $680 million. In July, the acquisition spree continued to EyeBio worth $3 billion, tackling diabetic macular edema and neovascular age-related macular degeneration. Lastly, Merck bought Elanco’s Aqua Business the same month for its Animal Health division and new-gen DNA-based vaccines.

These acquisitions paint a clear picture of Merck’s expansion and diversification. In Q2 earnings, the pharma giant reported $16.1 billion sales, up 7% from the year-ago quarter. Cancer-treating KEYTRUDA was responsible for the bulk of the revenue of $7.3 billion, up 21% notwithstanding foreign exchange impact.

Merck raised 2024 outlook to $63.4 – $64.4 billion sales range. Although Merck is yet to deliver its own AOM, it has a wide portfolio of drugs covering all major sectors. It is also notable that even without its own AOM, Merck can count on the rapid rise of common cancers. For 2024 alone, the American Cancer Society projected 2 million new cancer cases and 611k cancer deaths.

Presently priced at $114.57 per share, MRK stock is down 12.65% over the last three months, or up 1.2% YTD. Against the 52-week average of $117.73, the average MRK price target is $143.45. With the low estimate of $125 above the current price level, MRK also presents an enticing exposure but with a much wider pharma moat.

With a market share of 11.14% relative to its competitors as of Q2 2024, Merck only falls behind Johnson & Johnson (NYSE:JNJ) (15.43%) and Procter & Gamble Company (NYSE:PG) (14.98%).

***

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

Big Pharma Stocks: Who’s Leading the Race and Who’s Slipping?
 

Related Articles

Big Pharma Stocks: Who’s Leading the Race and Who’s Slipping?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email